Add Yahoo as a preferred source to see more of our stories on Google. Paris-based VC firm HCVC just announced the final closing of its second fund, simply called “Fund II.” And the team has managed to ...
Copenhagen, Feb. 25, 2025 (GLOBE NEWSWIRE) -- Gene therapy's biggest obstacle isn't science - it's manufacturing. While the field races forward with breakthrough treatments, production remains stuck ...
The MarketWatch News Department was not involved in the creation of this content. Paris, May 28, 2025 (GLOBE NEWSWIRE) -- One of the biggest challenges facing biologic drug developers are varying ...
Paris-based VC firm HCVC just announced the final closing of its second fund, simply called “Fund II.” And the team has managed to raise $75 million (€69 million) so that it can back pre-seed and seed ...
Paris, May 28, 2025 (GLOBE NEWSWIRE) -- One of the biggest challenges facing biologic drug developers are varying efficacy and the dangers of side effects. Biotechnology company kyron.bio today ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results